Document is current
Any future updates will be listed below
-
Authors
Petri, Karl https://orcid.org/0000-0002-9624-3976
D’Ippolito, Elvira https://orcid.org/0000-0003-0113-6797
Künkele, Annette
Köhl, Ulrike https://orcid.org/0000-0002-8159-9160
Busch, Dirk H. https://orcid.org/0000-0001-8713-093X
Einsele, Hermann https://orcid.org/0000-0002-7680-0819
Hudecek, Michael
- License Information
-
More Information
Article History
Accepted: 20 August 2025
First Online: 19 September 2025
Competing interests
: K.P. has a financial interest in and is an equity owner of SeQure Dx and is listed as an inventor on granted patents related to CRISPR technologies that have been filed by Massachusetts General Hospital. U.K. had received consultancy and/or speaker fees from Affimed, AstraZeneca, Bristol Myers Squibb (BMS) GammaDelta, Glycostem, Miltenyi Biotec, Novartis and Zelluna. H.E. declares consulting or advisory roles for and has received honoraria from Amgen, BMS/Celgene, GSK, Janssen, Novartis, Sanofi and Takeda; research funding from Amgen, BMS/Celgene, GSK, Janssen and Sanofi; and travel support from Amgen, BMS/Celgene, Janssen, Novartis, Sanofi and Takeda. M.H. is listed as an inventor on patent applications and granted patents related to CAR T cell technologies that have been filed by the Fred Hutchinson Cancer Research Center and by the University of Würzburg; is a cofounder and equity owner of T-CURX; has received honoraria from BMS/Celgene, Janssen and Kite/Gilead. E.D., A.K. and D.H.B. declare no competing interests.
